8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Jan 12, 2026·SEC
Nuvation Bio Inc.(NUVB)Earnings, Financials & Key Ratios
NUVB•NYSE
$4.83
$1.67B mkt cap·Price updated May 6, 2026
AboutNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.Show more
- Revenue$63M+699.0%
- EBITDA-$191M+67.7%
- Net Income-$205M+64.0%
- EPS (Diluted)-0.60+71.6%
- Gross Margin86.58%+757.4%
- EBITDA Margin-303.56%+96.0%
- Operating Margin-338.72%+95.5%
- Net Margin-325.31%+95.5%
- ROE-53.18%+50.0%
- ROIC-54.28%+38.7%
- Debt/Equity0.03+72.7%
- Interest Coverage-13.96+99.2%
NUVB Key Insights
Nuvation Bio Inc. (NUVB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 37.5% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 27.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NUVB Price & Volume
Nuvation Bio Inc. (NUVB) stock price & volume — 10-year historical chart
Loading chart...
NUVB Growth Metrics
Nuvation Bio Inc. (NUVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM1205.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM75.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.7%
Return on Capital
10 Years-40.63%
5 Years-40.68%
3 Years-55.78%
Last Year-42.83%
NUVB Recent Earnings
Nuvation Bio Inc. (NUVB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (83%)
Q2 2026Latest
May 4, 2026EPS
$0.01
Est $0.03
+135.7%
Revenue
$83M
Est $66M
+26.6%
Q2 2026
Mar 2, 2026EPS
$0.11
Est $0.11
+0.0%
Revenue
$42M
Est $38M
+10.7%
Q4 2025
Nov 3, 2025EPS
$0.16
Est $0.17
+5.9%
Revenue
$13M
Est $37M
-64.4%
Q3 2025
Aug 7, 2025EPS
$0.17
Est $0.17
+0.0%
Revenue
$5M
Est $4M
+33.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.01vs $0.03+135.7% | $83Mvs $66M+26.6% |
| Q2 2026 | Mar 2, 2026 | $0.11vs $0.11+0.0% | $42Mvs $38M+10.7% |
| Q4 2025 | Nov 3, 2025 | $0.16vs $0.17+5.9% | $13Mvs $37M-64.4% |
| Q3 2025 | Aug 7, 2025 | $0.17vs $0.17+0.0% | $5Mvs $4M+33.4% |
Based on last 12 quarters of dataView full earnings history →
NUVB Peer Comparison
Nuvation Bio Inc. (NUVB) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 6.75B | 82.71 | -22.41 | -16.72% | -6.12% | -25.02% | 0.05 | |
 TPST | 59.99M | 2.15 | -1.43 | -5.68% | 0.80 | |||
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 RVMD | 29B | 147.21 | -24.74 | -69.35% | 0.10 | |||
 AUPH | 2.12B | 16.04 | 7.75 | 20.38% | 101.47% | 49.4% | 6.38% | 0.13 |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 ARVN | 678.63M | 10.61 | -8.29 | -0.3% | -30.77% | -14.25% | 0.02 | |
 KRYS | 8.38B | 284.57 | 41.60 | 33.94% | 53.92% | 19.25% | 2.26% | 0.01 |
Compare NUVB vs Peers
Nuvation Bio Inc. (NUVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NUVB Income Statement
Nuvation Bio Inc. (NUVB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 7.87M | 62.9M | 143.05M |
| Revenue Growth % | - | - | - | - | - | - | - | 698.96% | 1205.52% |
| Cost of Goods Sold | 0 | 0 | 103K | 0 | 0 | 0 | 7.08M | 8.44M | 11.96M |
| COGS % of Revenue | - | - | - | - | - | - | 89.9% | 13.42% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -103K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 795K▲ 0% | 54.46M▲ 6750.3% | 131.08M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | 10.1% | 86.58% | 91.64% |
| Gross Profit Growth % | - | - | - | 100% | - | - | - | 6750.31% | - |
| Operating Expenses | 992K | 32.1M | 43.45M | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M | 281.26M |
| OpEx % of Revenue | - | - | - | - | - | - | 7537.43% | 425.3% | - |
| Selling, General & Admin | 509.33K | 6.99M | 10.85M | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M | 154.48M |
| SG&A % of Revenue | - | - | - | - | - | - | 879.37% | 240.95% | - |
| Research & Development | 482.67K | 25.11M | 32.6M | 69.04M | 87.81M | 71.29M | 524.19M | 115.11M | 125.55M |
| R&D % of Revenue | - | - | - | - | - | - | 6658.06% | 182.99% | - |
| Other Operating Expenses | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 856K | 1.23M |
| Operating Income | -992K▲ 0% | -32.1M▼ 3135.8% | -43.55M▼ 35.7% | -93.32M▼ 114.3% | -119.73M▼ 28.3% | -99.82M▲ 16.6% | -592.63M▼ 493.7% | -213.06M▲ 64.0% | -150.18M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | -7527.33% | -338.72% | -104.99% |
| Operating Income Growth % | - | -3135.79% | -35.68% | -114.27% | -28.31% | 16.63% | -493.68% | 64.05% | - |
| EBITDA | 0 | -32.09M | -43.45M | -93.13M | -119.53M | -99.6M | -591.94M | -190.94M | -145.17M |
| EBITDA Margin % | - | - | - | - | - | - | -7518.66% | -303.56% | -101.49% |
| EBITDA Growth % | - | - | -35.41% | -114.36% | -28.35% | 16.68% | -494.32% | 67.74% | 76.98% |
| D&A (Non-Cash Add-back) | 992K | 13K | 103K | 184K | 199K | 222K | 683K | 0 | 890K |
| EBIT | -992K | -32.1M | -41.66M | -93.32M | -119.73M | -75.8M | -567.6M | -190.94M | -143.8M |
| Net Interest Income | 0 | 1.37K | 1.95M | 2.96M | 7.45M | 24.61M | 26.72M | 7.75M | 2.48M |
| Interest Income | 0 | 1.37K | 1.95M | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M | 15.18M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 341K | 13.68M | 887K |
| Other Income/Expense | 0 | -1.45M | 1.89M | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M | 4.18M |
| Pretax Income | -992K▲ 0% | -33.55M▼ 3282.3% | -41.66M▼ 24.2% | -86.85M▼ 108.5% | -104.2M▼ 20.0% | -75.8M▲ 27.3% | -567.94M▼ 649.2% | -204.63M▲ 64.0% | -145.99M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | -7213.76% | -325.31% | -102.06% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -992K▲ 0% | -33.55M▼ 3282.3% | -41.66M▼ 24.2% | -86.85M▼ 108.5% | -104.2M▼ 20.0% | -75.8M▲ 27.3% | -567.94M▼ 649.2% | -204.63M▲ 64.0% | -145.99M▲ 0% |
| Net Margin % | - | - | - | - | - | - | -7213.76% | -325.31% | -102.06% |
| Net Income Growth % | - | -3282.26% | -24.16% | -108.47% | -19.98% | 27.25% | -649.24% | 63.97% | 75.92% |
| Net Income (Continuing) | -992K | -33.55M | -41.66M | -86.85M | -104.2M | -75.8M | -567.94M | -204.63M | -145.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -0.16▼ 2863.0% | -0.19▼ 18.8% | -0.44▼ 131.6% | -0.48▼ 9.1% | -0.35▲ 27.1% | -2.11▼ 502.9% | -0.60▲ 71.6% | -0.39▲ 0% |
| EPS Growth % | - | - | -18.75% | -131.58% | -9.09% | 27.08% | -502.86% | 71.56% | 81.7% |
| EPS (Basic) | -0.01 | -0.16 | -0.19 | -0.44 | -0.48 | -0.35 | -2.11 | -0.60 | - |
| Diluted Shares Outstanding | 183.74M | 206.67M | 217.65M | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M | 377.52M |
| Basic Shares Outstanding | 183.74M | 206.67M | 217.65M | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M | 347.33M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NUVB Balance Sheet
Nuvation Bio Inc. (NUVB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 158K | 119.89M | 220.68M | 772.07M | 667.32M | 616.43M | 526.25M | 571.52M | 591.53M |
| Cash & Short-Term Investments | 138K | 118.87M | 215.75M | 765.39M | 661.01M | 611.21M | 502.69M | 529.21M | 533.73M |
| Cash Only | 138K | 3.47M | 29.75M | 132.42M | 101.1M | 42.65M | 35.72M | 164.09M | 125.39M |
| Short-Term Investments | 0 | 115.4M | 186M | 632.97M | 559.91M | 568.56M | 466.97M | 365.13M | 408.34M |
| Accounts Receivable | 0 | 0 | 1.09M | 3.04M | 2.48M | 3.7M | 16.29M | 19.36M | 25.98M |
| Days Sales Outstanding | - | - | - | - | - | - | 755.31 | 112.35 | 42.02 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.41M | 15.84M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 493.37 | 255.64 |
| Other Current Assets | 0 | 828K | 2.92M | 0 | 3.82M | 1.52M | 7.27M | 11.54M | 15.97M |
| Total Non-Current Assets | 0 | 1.07M | 1.11M | 4.08M | 4.82M | 5.05M | 14.37M | 23.3M | 18.71M |
| Property, Plant & Equipment | 0 | 646K | 688K | 3.66M | 4.68M | 4.32M | 2.99M | 4.48M | 4.13M |
| Fixed Asset Turnover | - | - | - | - | - | - | 2.63x | 14.03x | 30.50x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 4.62M | 11.21M | 10.76M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 421K | 421K | 421K | 138K | 728K | 6.76M | 7.61M | 25.51M |
| Total Assets | 158K▲ 0% | 120.95M▲ 76451.9% | 221.79M▲ 83.4% | 776.15M▲ 249.9% | 672.14M▼ 13.4% | 621.48M▼ 7.5% | 540.63M▼ 13.0% | 594.82M▲ 10.0% | 610.24M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.01x | 0.11x | 0.23x |
| Asset Growth % | - | 76451.9% | 83.37% | 249.95% | -13.4% | -7.54% | -13.01% | 10.02% | 47.99% |
| Total Current Liabilities | 902K | 3.2M | 6.55M | 16.93M | 13.16M | 13.97M | 58.24M | 82.23M | 79.52M |
| Accounts Payable | 83K | 2.03M | 2.17M | 3.92M | 2.14M | 2.21M | 6.35M | 9.48M | 22.43M |
| Days Payables Outstanding | - | - | 7.69K | - | - | - | 327.36 | 409.84 | 531.55 |
| Short-Term Debt | 600K | 0 | 0 | 0 | 0 | 0 | 6.28M | 7.6M | 7.63M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 11.12M | 0 | 16.45M |
| Other Current Liabilities | 0 | 11K | 3.23M | 6.17M | 3.99M | 4.35M | 14.82M | 65.15M | 71.89M |
| Current Ratio | 0.18x | 37.42x | 33.69x | 45.62x | 50.70x | 44.11x | 9.04x | 6.95x | 6.95x |
| Quick Ratio | 0.18x | 37.42x | 33.69x | 45.62x | 50.70x | 44.11x | 9.04x | 6.81x | 6.81x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 195.88 | -233.9 |
| Total Non-Current Liabilities | 0 | 0 | 157K | 13.23M | 3.9M | 2.39M | 18.59M | 206.88M | 211.16M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.54M | 2.2M |
| Capital Lease Obligations | 0 | 0 | 0 | 2.19M | 3.05M | 2.04M | 969K | 0 | 6.37M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 157K | 11.04M | 850K | 353K | 2.05M | 58.51M | 407.07M |
| Total Liabilities | 902K | 3.2M | 6.71M | 30.15M | 17.07M | 16.36M | 76.84M | 289.11M | 290.68M |
| Total Debt | 600K | 0 | 0 | 3.06M | 4.26M | 4.01M | 8.91M | 10.15M | 9.83M |
| Net Debt | 462K | -3.47M | -29.75M | -129.37M | -96.84M | -38.64M | -26.81M | -153.94M | -115.56M |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.02x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.07x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.80x |
| Interest Coverage | - | - | - | - | - | - | -1664.51x | -13.96x | -162.11x |
| Total Equity | -744K▲ 0% | 117.75M▲ 15926.3% | 215.08M▲ 82.7% | 746M▲ 246.8% | 655.08M▼ 12.2% | 605.12M▼ 7.6% | 463.79M▼ 23.4% | 305.72M▼ 34.1% | 319.56M▲ 0% |
| Equity Growth % | - | 15926.34% | 82.66% | 246.84% | -12.19% | -7.63% | -23.36% | -34.08% | -48.08% |
| Book Value per Share | -0.00 | 0.57 | 0.99 | 3.77 | 3.02 | 2.76 | 1.73 | 0.90 | 0.85 |
| Total Shareholders' Equity | -744K | 117.75M | 215.08M | 746M | 655.08M | 605.12M | 463.79M | 305.72M | 319.56M |
| Common Stock | 0 | 9.76M | 289.48M | 909.99M | 927.6M | 947.75M | 1.37B | 1.42B | 1.43B |
| Retained Earnings | -744K | -34.3M | -75.95M | -162.8M | -267M | -342.8M | -910.74M | -1.12B | -1.11B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 421K | 1.56M | -1.19M | -5.53M | 181K | 573K | -187K | -1.68M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NUVB Cash Flow Statement
Nuvation Bio Inc. (NUVB) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -616K | -24.43M | -36.53M | -68.19M | -96.11M | -68M | -130.41M | -173.43M | -173.43M |
| Operating CF Margin % | - | - | - | - | - | - | -1656.46% | -275.71% | - |
| Operating CF Growth % | - | -3866.23% | -49.51% | -86.67% | -40.94% | 29.25% | -91.79% | -32.98% | 48.45% |
| Net Income | -992K | -33.55M | -41.66M | -86.85M | -104.2M | -75.8M | -567.94M | -204.63M | -145.99M |
| Depreciation & Amortization | 0 | 13K | 103K | 184K | 199K | 222K | 683K | 1.74M | -310K |
| Stock-Based Compensation | 0 | 0 | 2.2M | 9.27M | 16.29M | 19.51M | 32.27M | 0 | -7.85M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 110.67K | 9.57M | 715K | 4.41M | -4.95M | -12.47M | 417.07M | 41.44M | -173.44M |
| Working Capital Changes | 265.33K | -460K | 2.11M | 4.79M | -3.45M | 540K | -12.51M | -11.98M | -2.76M |
| Change in Receivables | 0 | 0 | -264K | -1.95M | 554K | -1.22M | -12.59M | -3.07M | -10.83M |
| Change in Inventory | 0 | 0 | 264K | 0 | 0 | 0 | 0 | -11.41M | 14K |
| Change in Payables | 0 | 0 | 34K | 1.86M | -1.79M | 70K | -1.65M | 3.13M | -4.19M |
| Cash from Investing | 0 | -115.86M | -70.32M | -454.67M | 63.46M | 8.92M | 122.7M | 99.52M | 1.7M |
| Capital Expenditures | 0 | -659K | -145K | -282K | -370K | -69K | -162K | -8.35M | 72K |
| CapEx % of Revenue | - | - | - | - | - | - | 2.06% | 13.28% | - |
| Acquisitions | 0 | 0 | -2.51M | 0 | 0 | 0 | 12.43M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -115.2M | 2.51M | 0 | 13K | 14K | 0 | 0 | 55.88M |
| Cash from Financing | 800K | 143.62M | 133.13M | 625.53M | 1.33M | 628K | 331K | 202.53M | 202.03M |
| Debt Issued (Net) | 0 | 14.99M | 0 | 0 | 0 | 0 | -4.55M | 191.11M | 534K |
| Equity Issued (Net) | 0 | 0 | 135.66M | 0 | 0 | 0 | 4.88M | 11.42M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 800K | 128.63M | -2.52M | 625.53M | 1.33M | 628K | 0 | 0 | 201.5M |
| Net Change in Cash | 184K▲ 0% | 3.33M▲ 1710.4% | 26.29M▲ 689.1% | 102.67M▲ 290.6% | -31.32M▼ 130.5% | -58.45M▼ 86.6% | -6.93M▲ 88.2% | 128.36M▲ 1953.3% | 77.41M▲ 0% |
| Free Cash Flow | -616K▲ 0% | -25.09M▼ 3973.2% | -36.67M▼ 46.2% | -68.47M▼ 86.7% | -96.48M▼ 40.9% | -68.07M▲ 29.4% | -130.57M▼ 91.8% | -173.78M▼ 33.1% | -126.01M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | -1658.52% | -276.27% | -88.09% |
| FCF Growth % | - | -3973.21% | -46.16% | -86.7% | -40.9% | 29.45% | -91.83% | -33.09% | 20.01% |
| FCF per Share | -0.00 | -0.12 | -0.17 | -0.35 | -0.45 | -0.31 | -0.49 | -0.51 | -0.51 |
| FCF Conversion (FCF/Net Income) | 0.62x | 0.73x | 0.88x | 0.79x | 0.92x | 0.90x | 0.23x | 0.85x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 341K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 373K | 0 | 0 |
NUVB Key Ratios
Nuvation Bio Inc. (NUVB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -57.35% | -25.03% | -18.07% | -14.87% | -12.03% | -106.27% | -53.18% | -44.1% |
| Return on Invested Capital (ROIC) | -42.24% | -21.8% | -17.45% | -15.29% | -13.31% | -88.59% | -54.28% | -54.28% |
| Gross Margin | - | - | - | - | - | 10.1% | 86.58% | 91.64% |
| Net Margin | - | - | - | - | - | -7213.76% | -325.31% | -102.06% |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.02x | 0.03x | 0.03x |
| Interest Coverage | - | - | - | - | - | -1664.51x | -13.96x | -162.11x |
| FCF Conversion | 0.73x | 0.88x | 0.79x | 0.92x | 0.90x | 0.23x | 0.85x | 0.86x |
| Revenue Growth | - | - | - | - | - | - | 698.96% | 1205.52% |
NUVB SEC Filings & Documents
Nuvation Bio Inc. (NUVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
NUVB Frequently Asked Questions
Nuvation Bio Inc. (NUVB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nuvation Bio Inc. (NUVB) reported $143.0M in revenue for fiscal year 2025.
Nuvation Bio Inc. (NUVB) grew revenue by 699.0% over the past year. This is strong growth.
Nuvation Bio Inc. (NUVB) reported a net loss of $146.0M for fiscal year 2025.
Dividend & Returns
Nuvation Bio Inc. (NUVB) has a return on equity (ROE) of -53.2%. Negative ROE indicates the company is unprofitable.
Nuvation Bio Inc. (NUVB) had negative free cash flow of $126.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More NUVB
Nuvation Bio Inc. (NUVB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates